3,501 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Perpetual Ltd

Perpetual Ltd acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,501 shares of the biotechnology company’s stock, valued at approximately $230,000.

Several other institutional investors also recently bought and sold shares of BMRN. Erste Asset Management GmbH bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $48,527,000. Assenagon Asset Management S.A. raised its holdings in BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after buying an additional 502,695 shares in the last quarter. Vestal Point Capital LP bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $28,116,000. Clearline Capital LP bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $22,477,000. Finally, Dimensional Fund Advisors LP raised its holdings in BioMarin Pharmaceutical by 38.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock valued at $85,178,000 after buying an additional 289,953 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Up 0.3 %

Shares of BMRN opened at $62.19 on Friday. The stock has a market cap of $11.85 billion, a price-to-earnings ratio of 37.24, a P/E/G ratio of 0.55 and a beta of 0.29. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a 50-day moving average price of $65.22 and a two-hundred day moving average price of $73.93.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The business had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the prior year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. Equities analysts predict that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current fiscal year.

Insider Activity

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.85% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BMRN shares. William Blair lowered BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Robert W. Baird lowered their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Citigroup lowered their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $80.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. Finally, Evercore ISI lowered their price target on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.